*NURSING > STUDY GUIDE > NR566 Final Study Guide Outline With complete and new Focused information you need for your Exam.(Ch (All)

NR566 Final Study Guide Outline With complete and new Focused information you need for your Exam.(Chamberlain College of Nursing) RATED A

Document Content and Description Below

NR566 Final Study Guide Outline With complete and new Focused information you need for your Exam.(Chamberlain College of Nursing) RATED ANR566 Final Study Guide Outline With complete and new Focused i... nformation you need for your Exam.(Chamberlain College of Nursing) RATED A Pharmacodynamics • Oral anticoagulants such as warfarin (Coumadin) inhibit the hepatic synthesis of several clotting factors, including factor X. • Heparin inhibits the activity of several activated clotting factors by accelerating the activity of antithrombin III. • LMWH enoxaparin (Lovenox) potentiates the activity of antithrombin III and inactivates factors Xa and IIa (thrombin). • Dabigatran (Pradaxa) is a direct thrombin inhibitor. • Thrombin is required for the conversion of fibrinogen to fibrin in the clotting cascade, thus dabigatran's inhibition of thrombin prevents thrombi from forming.  Fondaparinux (Arixtra) is a selective inhibitor of antithrombin III and a factor Xa inhibitor.  Rivaroxaban (Xarelto) an anticoagulant, is a highly selective factor Xa inhibitor that inhibits thrombin formation and the development of thrombi.  Apixaban (Eliquis) is a selective inhibitor of factor Xa. • Aspirin antagonizes the cyclooxygenase pathway and interferes with platelet aggregation. • NSAIDs have this same action. • NSAIDs are not used as antiplatelet drugs, but this explains why concurrent use with anticoagulants is contraindicated • Ticlopidine (Ticlid) and clopidogrel (Plavix) reduce platelet aggregation by inhibiting the ADP pathway of platelets. • Unlike aspirin, they have no effect on prostaglandin metabolism. • Ticagrelor (Brilinta) reversibly interacts with the platelet P2Y12 ADP-receptor to prevent platelet activation. • Vorapaxar (Zontivity) is a protease-activated receptor-1 (PAR-1) antagonist, inhibiting thrombin-induced and thrombin receptor agonist peptide-induced platelet aggregation [Show More]

Last updated: 1 year ago

Preview 1 out of 93 pages

Reviews( 0 )

$18.00

Add to cart

Instant download

Can't find what you want? Try our AI powered Search

OR

GET ASSIGNMENT HELP
52
0

Document information


Connected school, study & course


About the document


Uploaded On

Oct 05, 2021

Number of pages

93

Written in

Seller


seller-icon
VERIFIED A+

Member since 3 years

80 Documents Sold


Additional information

This document has been written for:

Uploaded

Oct 05, 2021

Downloads

 0

Views

 52

Document Keyword Tags

Recommended For You


$18.00
What is Browsegrades

In Browsegrades, a student can earn by offering help to other student. Students can help other students with materials by upploading their notes and earn money.

We are here to help

We're available through e-mail, Twitter, Facebook, and live chat.
 FAQ
 Questions? Leave a message!

Follow us on
 Twitter

Copyright © Browsegrades · High quality services·